-

DNA Script to Present at 40th Annual J.P. Morgan Healthcare Conference

Company to Present Monday, January 10, 2022, at 2 p.m. EST

SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--DNA Script, a leader in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, today announced that its CEO and co-founder Thomas Ybert, Ph.D., will present on the Company’s growth and vision at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually. Ybert’s session will take place on Monday, January 10, 2022, at 11:00 a.m. PST / 2:00 p.m. EST.

Registered attendees may access sessions at the following link during the conference: https://jpmorgan.metameetings.net/events/healthcare22.

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, and is deploying it with the first-ever in-house, benchtop enzymatic synthesis system, the SYNTAX Platform. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com

Contacts

Press contacts in the US
Seismic
Valerie Enes
415-692-6799
valerie@teamseismic.com

DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co

Press contact in Europe
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

Industry:

DNA Script

Release Summary
DNA Script to Present at 40th Annual J.P. Morgan Healthcare Conference
Release Versions
English

Contacts

Press contacts in the US
Seismic
Valerie Enes
415-692-6799
valerie@teamseismic.com

DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co

Press contact in Europe
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

More News From DNA Script

DNA Script Strengthens Its Management Team with the Appointment of Bruno Poddevin as Senior Vice President of Business and Corporate Development

PARIS--(BUSINESS WIRE)--DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, further strengthened its leadership team with the addition of Bruno Poddevin, Ph.D., who brings 30 years of experience in the oligo manufacturing industry to the role of Senior VP, Business and Corporate Development. In his new position, Poddevin will manage DNA Script’s external collaborations and partnerships, targeting a faster integration of EDS into established as well as innovative molec...

DNA Script Extends Distributorships to Middle East to Expand Access to Same-day Enzymatic DNA Synthesis

SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has signed distribution agreements in the Middle East with Gulf Scientific Corporation (Bahrain, KSA, Kuwait, Oman, Qatar and UAE) and Eisenberg Ltd. (Israel) to expand its worldwide footprint of sales, service and support. New distribution partner Kiko Tech, Ltd. (Japan) extends the company’s existing channel network in the Asia-Pacific (APAC) region. Like APAC,...

DNA Script Wins the Grand Prize Trophy at the 2022 French Future Unicorns Ceremony

SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel (Paris). Of the 1400 French companies initially identified for consideration, a jury narrowed them down to 250 that met the criteria, from which DNA Script was selected as the Grand Prize winner. "DNA Script is honored to receive...
Back to Newsroom